Učitavanje...
Role of CD20 Monoclonal Antibodies in Previously Untreated Chronic Lymphocytic Leukemia
Monoclonal antibodies (mAbs) directed against the CD20 antigen on B cells have dramatically altered the treatment landscape for patients with chronic lymphocytic leukemia (CLL). Rituximab, a chimeric mouse/human mAb, was the first antibody to be approved for treatment of indolent B cell lymphomas. A...
Spremljeno u:
| Izdano u: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2010
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4624201/ https://ncbi.nlm.nih.gov/pubmed/20529805 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CLML.2010.s.004 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|